by support | Nov 28, 2022 | Uncategorized
Our continuing education-accredited conference is a groundbreaking opportunity for health care providers, researchers, patients, families, and caregivers to learn about the latest advances in research, treatment, and care from leaders in the field of nontuberculous...
by support | Nov 28, 2022 | Uncategorized
ARIKAYCE® is currently the only FDA approved drug designed specifically for NTM (MAC) and now available through prescription from your physician for treatment of refractory MAC lung infection in adult patients. This medication is only available through select...
by support | Nov 28, 2022 | Uncategorized
Every day, NTM Info & Research’s commitment to finding therapies serves as hope for the NTM community. We are constantly looking for ways to boost our financial support of research to achieve better treatments and, eventually, a cure. Until that cure is found, we...
by support | Nov 28, 2022 | Uncategorized
On April 8th, 2019 the U.S. Food & Drug Administration will host a public workshop on the development of antibacterial drugs for the treatment of nontuberculous mycobacterial (NTM) infection.
